article thumbnail

Lilly preps for rollout of its connected diabetes system

pharmaphorum

Taken together, the system can support patients with medication reminders, education resources, insulin dose logging and feedback on blood glucose levels, while a hub for physicians called Tempo Insights to help them make decisions about patient care based on data. The system works as follows.

article thumbnail

Too Much of a Good Thing? Unpacking the Rise of Polypharmacy in Seniors

PharmD Live

Understanding the balance between essential and excessive polypharmacy, recognizing its prevalence, and identifying contributing factors are crucial in mitigating its risks and enhancing patient care. At this rate, nearly half of the older population could be impacted by polypharmacy by 2030. According to the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sustainability Definitions for the Pharmaceutical Industry

ISPE

The pharmaceutical industry commits substantial resources in new medicines and treatment options to combat a variety of illnesses and diseases affecting communities globally. while meeting patient needs as a primary goal. Transforming Our World: The 2030 Agenda for Sustainable Development.” 7 December 2017. October 2015.

article thumbnail

Osteopathic Medicine and Surviving Your Second Year of Medical School with Dr. Bryce Brohol ?

The Physician Pharmacist

I felt like I had made the correct decision, not only because I didn't really enjoy the pharmacy aspect as much, there's no doubt that pharmacists have an immense importance in the medical field and patient care. A lot of projects are not going to take up 2030 hours a week.

article thumbnail

Sandoz targets barriers to biosimilar accessibility with latest initiative

Pharmaceutical Technology

Unsustainable procurement practices such as single-winner tenders seen in Mexico and Brazil were also highlighted as a source of drug supply continuity risks and overall disruptions to patient care. This comes as part of the company’s Act4Biosimilars initiative launched last year. Please check your email to download the Report.